A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Caba, Buenos Aires C1090AAS, Argentina
Federal District, 72115700, Belgium
Chongqing, Sichuan 400030, China
North Rhine-Westphalia, 45136, Germany
Kashiwa-shi, Chiba 2778577, Japan
Abeno-ku, Osaka 5458586, Japan
Iruma-gun, Saitama 3500495, Japan
Izunokuni-shi, Shizuoka 410-2295, Japan
Minato-ku, Tokyo 105-8470, Japan
Musashino-shi, Tokyo 180-8610, Japan
Guro-gu, Seoul 8308, South Korea
Jongno-gu, Seoul 03080, South Korea
Gyeongsangnam-do, 050612, South Korea